a distinctive phenotype including facial dysmorphias, global developmental delay, severe intellectual disability, and hyperventilation episodes (Marangi & Zollino, 2015; Sweatt, 2013; Whalen et al., 2012) .
PTHS has a relatively short history of clinical and genetic investigation: its rarity and similarity to other well recognized syndromes has hampered the efforts for a deeper understanding of the underlying pathological mechanisms. It is only in the last decade that PTHS has emerged as a clinically and genetically defined entity (Whalen et al., 2012; Zweier et al., 2007) .
On the molecular level, PTHS is caused by mutations or variable size deletions involving the gene encoding basic helix-loop-helix transcription factor 4 (TCF4, OMIM 602272) located on 18q21 (Amiel et al., 2007; Brockschmidt et al., 2007; Hasi et al., 2011; Zweier et al., 2007) .
The involvement of TCF4 was first demonstrated in 2006 (Peippo et al., 2006) and to this day more than 200 PTHS patients with TCF4 point mutations or deletions have been reported (Marangi & Zollino, 2015) with the sizes of deletions ranging from 63 kb (Brockschmidt et al., 2007) to 13 Mb (Gustavsson, Kimber, Wahlstrom, & Anneren, 1999) .
Literature on mosaic TCF4 deletions is limited because of their rarity and interpretation challenges (Giurgea et al., 2008; Rossi et al., 2012; Stavropoulos, MacGregor, & Yoon, 2010) .
In this research letter we describe a unique mosaic TCF4 deletion in a girl with phenotype highly suggestive of PTHS (Family 1).
This new finding is discussed in the light of a previous publication by our group (Family 2), where the phenotypically normal father of a PTHS patient carries a mosaic TCF4 deletion which is inherited in full by his affected son (Kousoulidou et al., 2013) . Most PTHS occurrences so far are caused by de novo events; only in three cases the causative mutations/deletions were inherited from a mosaic parent, namely the father of Family 2, the unaffected mosaic female mentioned above (Steinbusch et al., 2013) and the mosaic female with depression presented on Table 1 (de Pontual et al., 2009 ). In these rare instances the detection of parental germline mosaicism is crucial for genetic counseling, as it defines the exact origin of the aberration and indicates a significantly increased recurrence risk requiring targeted prenatal diagnosis in future pregnancies. Novel genetic testing techniques, in combination with traditional cytogenetic approaches such as karyotype and FISH will enable accurate identification of mosaicism within the frame of routine genetic investigation.
Mosaicism detection is vital not only for assessment of PTHS inheritance, but also for prediction of possible phenotypic outcomes in affected mosaic individuals or foetuses with prenatal ultrasound abnormalities, the latter being far more challenging for genetic counseling. The accumulation of clinical and genetic data on mosaic cases would enable deeper understanding of TCF4--PTHS correlation, which is currently unclear: because TCF4 gene has important functions (Peippo & Ignatius, 2012) , aberrations in the gene can affect several organs; consequently, some patients carrying TCF4 abnormalities may not be classified as PTHS because of atypical phenotype, not resembling those described in original publications (Peippo et al., 2006; Pitt & Hopkins, 1978) . Genotype-phenotype correlations are expected to create the background for predictions that are valuable to the families involved. FIGURE 2 Metaphase FISH analysis of patient 1 using the locus specific probe RP11-7L24 located on 18q21.2 (red arrows) and the internal control probe RP11-288C17 located on 18p11.32 (green arrows). The mosaicism of TCF4 deletion is confirmed by the presence of metaphases with normal copy number (above) along with metaphases carrying the TCF4 deletion (below) [Color figure can be viewed at wileyonlinelibrary.com] given the wide variability found in different patients (Marangi & Zollino, 2015; Whalen et al., 2012) . Despite the small size of the deletion in Family 2, it removes some of the critical exons (Kalscheuer et al., 2008) and affects all 47 transcripts of TCF4 (Sepp, Kannike, Eesmaa, Urb, & Timmusk, 2011) , hence the affected child carries the key clinical features of PTHS. When comparing the affected individuals from the two families, it is difficult to determine whether or not the size of deletion is an important factor in the phenotype severity, since one of the patients carries a larger deletion but in a mosaic state. Some studies suggest that larger deletions including contiguous genes add to the phenotype severity (Kato, Morimoto, Kimura, Matsushima, & Kondo, 2010; Marangi & Zollino, 2015) , whereas other studies show no significant phenotypic differences between various size deletions and even point mutations, confirming TCF4 haploinsufficiency as the main pathogenic mechanism of PTHS (Giurgea et al., 2008) . Currently the phenotypic variation among PTHS patients is not fully understood and not always correlates with the size of deletions detected in different patients. For this reason, epigenetic modifications, variable expressivity and genetic background are among the factors that should be taken into account.
In our research letter we have once again highlighted that accurate diagnosis can only be achieved by combining clinical evaluation with detailed genetic profiling, especially for syndromes with phenotypic and genetic variability such as PTHS. Current and future developments in genetic testing will lead to more PTHS patients being diagnosed, thereby increasing the variability of PTHS phenotype, further defining the boundaries of PTHS spectrum. In addition, we have demonstrated the wide range of possible phenotypic outcomes in individuals carrying mosaic TCF4 mutations--from severe PTHS to a completely normal phenotype. For these rare and challenging cases, tissue specificity would be an exciting new focus for further studies.
This information is vital for a more accurate diagnosis, prognosis and management. Clinical and molecular characterization of carriers of TCF4 mosaic deletions and/or mutations contributes to our understanding of the pathogenic mechanisms leading to PTHS.
ACKNOWLEDGMENT
The authors would like to thank the patients and their families for participating in the study.
CONFLICT OF INTEREST
None.
ORCID

Ludmila Kousoulidou
https://orcid.org/0000-0002-9774-262X
Carolina Sismani https://orcid.org/0000-0002-9296-8347
